2 Corporate Drive
South San Francisco
19 articles with PACT Pharma
Nature Paper from PACT Pharma and UCLA Highlights How Patients with Cancer Respond Differently to Anti-PD-1 Therapy
PACT Pharma, Inc. today announced the publication of a peer-reviewed paper in Nature in collaboration with researchers at University of California, Los Angeles (UCLA) detailing groundbreaking work characterizing and differentiating the immune responses of melanoma patients treated with anti PD-1 immunotherapy.
PACT Pharma shared results of a first-of-its-kind trial using CRISPR technology to swap a gene in a patient’s immune cell to treat solid tumors.
PACT Pharma Reports Data From First Clinical Study Using CRISPR to Substitute a Gene in Patients' Immune Cells to Treat Cancer
PACT Pharma, Inc. today reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients' immune cells to treat cancer.
PACT Pharma to Present New Data Highlighting First-of-its-Kind Personalized Neoantigen TCR T Cell Therapy Platform at SITC 2022
PACT Pharma, Inc. today announced that new data highlighting its first-of-its-kind adoptive T cell therapy platform will be featured in multiple presentations at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022).
PACT Pharma Announces Agreement to Sell Select Assets to AmplifyBio
PACT Pharma, Inc. announced that it has entered into an agreement to sell select assets to AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities.
Amplifybio Acquires PACT Pharma Assets to Enhance Cell and Gene Therapy Characterization Capabilities
AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities; announced the acquisition of select assets from PACT Pharma, Inc., a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies.
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
The poster presentation reported research findings by PACT scientists demonstrating the ability to utilize the company’s PACT^NV technology to generate TCR T cells in a single step.
PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022
PACT Pharma, Inc. today announced that new data highlighting several aspects of its first-of-its-kind personalized neoantigen platform for adoptive cell therapies were presented in five separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.
PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, announced that new data related to its PACTImmune™ Database were presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting.
Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.
PACT Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39 th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT / 10:30 a.
Cellares Adds PACT Pharma to its Early Access Partnership Program
- Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount - PACT Pharma is the second organization and first industry partner to join the program following Fred Hutchinson Cancer Research Center
Lyell Immunopharma and PACT Pharma Announce Research and Clinical Development Partnership
--Companies will leverage their highly complementary technologies to address target specificity for tumor cells and cell exhaustion, two significant barriers for solid tumor T cell therapy--
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
PACT Pharma Appoints Uneek Mehra as Chief Financial Officer
Mehra brings significant experience scaling organizations, an important skill as PACT grows and enters the clinic.
PACT Pharma Appoints Tim Moore as President and Chief Technical Officer
Moore led development of one of only two FDA-approved CAR-T therapies.
Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
PACT's gene-edited T cells were observed to kill tumor cells by targeting patient-specific tumor mutation targets in non-clinical testing
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.